Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA 94158, USA.
Institute for Human Genetics, University of California San Francisco, San Francisco, CA 94158, USA.
Science. 2019 Jan 18;363(6424). doi: 10.1126/science.aau0629. Epub 2018 Dec 13.
A wide range of human diseases result from haploinsufficiency, where the function of one of the two gene copies is lost. Here, we targeted the remaining functional copy of a haploinsufficient gene using CRISPR-mediated activation (CRISPRa) in and heterozygous mouse models to rescue their obesity phenotype. Transgenic-based CRISPRa targeting of the promoter or its distant hypothalamic enhancer up-regulated its expression from the endogenous functional allele in a tissue-specific manner, rescuing the obesity phenotype in heterozygous mice. To evaluate the therapeutic potential of CRISPRa, we injected CRISPRa-recombinant adeno-associated virus into the hypothalamus, which led to reversal of the obesity phenotype in and haploinsufficient mice. Our results suggest that endogenous gene up-regulation could be a potential strategy to treat altered gene dosage diseases.
多种人类疾病是由单倍不足引起的,即两个基因拷贝中的一个的功能丧失。在这里,我们使用 CRISPR 介导的激活(CRISPRa)靶向和杂合子小鼠模型中一个单倍不足基因的剩余功能拷贝,以挽救它们的肥胖表型。基于转基因的 CRISPRa 靶向的启动子或其遥远的下丘脑增强子以组织特异性的方式上调其从内源性功能等位基因的表达,挽救杂合子小鼠的肥胖表型。为了评估 CRISPRa 的治疗潜力,我们将 CRISPRa 重组腺相关病毒注射到下丘脑,这导致和杂合子小鼠肥胖表型的逆转。我们的结果表明,内源性基因上调可能是治疗改变基因剂量疾病的一种潜在策略。